Dr. Binusha Moitheennazima, MD
What this data tells you about Dr. Moitheennazima
Dr. Binusha Moitheennazima is a pulmonary disease in Nacogdoches, TX, with 17 years in practice. Based on federal Medicare data, Dr. Moitheennazima performed 13,478 Medicare services across 3,572 unique beneficiaries.
Between the years covered by Open Payments, Dr. Moitheennazima received a total of $9,216 from 39 pharmaceutical and/or device companies across 464 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Moitheennazima is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) | 2,946 | $94 | $439 |
| Allergy skin test | 2,168 | $3 | $13 |
| Allergy immunotherapy preparation | 2,055 | $11 | $53 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 1,072 | $27 | $134 |
| Dexamethasone injection (steroid) | 930 | $0 | $10 |
| Ceftriaxone antibiotic injection | 912 | $0 | $5 |
| Drug injection, under skin or into muscle | 509 | $10 | $49 |
| Test to determine lung volumes using sensors | 330 | $39 | $187 |
| Test to examine how well the lungs exchange gases | 329 | $41 | $201 |
| Hospital follow-up visit, moderate complexity | 319 | $63 | $242 |
| Nursing facility visit, moderate complexity | 314 | $80 | $336 |
| Critical care, first 30-74 min | 263 | $168 | $949 |
| Detection test by immunoassay with direct visual observation for influenza virus | 246 | $16 | $52 |
| Flu vaccine administration | 177 | $30 | $39 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 167 | $34 | $125 |
| Influenza vaccine, quadrivalent derived from cell cultures | 143 | $31 | $175 |
| Sleep study including heart rate, breathing, airflow, and effort | 97 | $70 | $315 |
| Injection, methylprednisolone acetate, 40 mg | 92 | $5 | $41 |
| New patient office visit (45-59 min) | 73 | $129 | $571 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 62 | $476 | $2,187 |
| Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | 51 | $135 | $558 |
| Initial hospital admission, high complexity | 50 | $138 | $671 |
| Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | 38 | $33 | $84 |
| Sleep study in sleep lab (6 years or older) | 32 | $466 | $2,088 |
| Sleep study including heart rate, breathing, and sleep time | 26 | $116 | $551 |
| Office visit, established patient (20-29 min) | 24 | $68 | $310 |
| Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | 22 | $41 | $125 |
| Allergy injection therapy, multiple injections | 20 | $9 | $39 |
| Transitional care management services for problem of high complexity | 11 | $216 | $958 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Moitheennazima is a clinical cardiology specialist, with above-average Medicare volume (top 0% in TX), and low-engagement industry engagement, with 17 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Moitheennazima experienced with office visit, established patient (30-39 min)?
Does Dr. Moitheennazima receive payments from pharmaceutical companies?
How do Dr. Moitheennazima's costs compare to other pulmonary diseases in Nacogdoches?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology